947 related articles for article (PubMed ID: 26065721)
1. Sarcopenic obesity: A probable risk factor for dose limiting toxicity during neo-adjuvant chemotherapy in oesophageal cancer patients.
Anandavadivelan P; Brismar TB; Nilsson M; Johar AM; Martin L
Clin Nutr; 2016 Jun; 35(3):724-30. PubMed ID: 26065721
[TBL] [Abstract][Full Text] [Related]
2. Sarcopenia is associated with toxicity in patients undergoing neo-adjuvant chemotherapy for oesophago-gastric cancer.
Tan BH; Brammer K; Randhawa N; Welch NT; Parsons SL; James EJ; Catton JA
Eur J Surg Oncol; 2015 Mar; 41(3):333-8. PubMed ID: 25498359
[TBL] [Abstract][Full Text] [Related]
3. Association between body composition, survival, and toxicity in advanced esophagogastric cancer patients receiving palliative chemotherapy.
Dijksterhuis WPM; Pruijt MJ; van der Woude SO; Klaassen R; Kurk SA; van Oijen MGH; van Laarhoven HWM
J Cachexia Sarcopenia Muscle; 2019 Feb; 10(1):199-206. PubMed ID: 30666831
[TBL] [Abstract][Full Text] [Related]
4. Impact of body composition parameters on clinical outcomes in patients with metastatic castrate-resistant prostate cancer treated with docetaxel.
Cushen SJ; Power DG; Murphy KP; McDermott R; Griffin BT; Lim M; Daly L; MacEneaney P; O' Sullivan K; Prado CM; Ryan AM
Clin Nutr ESPEN; 2016 Jun; 13():e39-e45. PubMed ID: 28531567
[TBL] [Abstract][Full Text] [Related]
5. Sarcopenia during neoadjuvant therapy for oesophageal cancer: characterising the impact on muscle strength and physical performance.
Guinan EM; Doyle SL; Bennett AE; O'Neill L; Gannon J; Elliott JA; O'Sullivan J; Reynolds JV; Hussey J
Support Care Cancer; 2018 May; 26(5):1569-1576. PubMed ID: 29197960
[TBL] [Abstract][Full Text] [Related]
6. Skeletal muscle mass correlates with increased toxicity during neoadjuvant radiochemotherapy in locally advanced esophageal cancer: A SAKK 75/08 substudy.
Panje CM; Höng L; Hayoz S; Baracos VE; Herrmann E; Garcia Schüler H; Meier UR; Henke G; Schacher S; Hawle H; Gérard MA; Ruhstaller T; Plasswilm L;
Radiat Oncol; 2019 Sep; 14(1):166. PubMed ID: 31511012
[TBL] [Abstract][Full Text] [Related]
7. Characterising the impact of body composition change during neoadjuvant chemotherapy for pancreatic cancer.
Griffin OM; Duggan SN; Ryan R; McDermott R; Geoghegan J; Conlon KC
Pancreatology; 2019 Sep; 19(6):850-857. PubMed ID: 31362865
[TBL] [Abstract][Full Text] [Related]
8. Skeletal muscle mass as a predictor of the response to neo-adjuvant chemotherapy in locally advanced esophageal cancer.
Ota T; Ishikawa T; Endo Y; Matsumura S; Yoshida J; Yasuda T; Okayama T; Inoue K; Dohi O; Yoshida N; Sakamoto N; Kamada K; Uchiyama K; Takagi T; Konishi H; Konishi H; Shiozaki A; Fujiwara H; Kishimoto M; Naito Y; Itoh Y
Med Oncol; 2019 Jan; 36(2):15. PubMed ID: 30600347
[TBL] [Abstract][Full Text] [Related]
9. Sarcopenia and sarcopenic obesity are independent adverse prognostic factors in resectable pancreatic ductal adenocarcinoma.
Gruber ES; Jomrich G; Tamandl D; Gnant M; Schindl M; Sahora K
PLoS One; 2019; 14(5):e0215915. PubMed ID: 31059520
[TBL] [Abstract][Full Text] [Related]
10. Sarcopenia and cachexia in the era of obesity: clinical and nutritional impact.
Prado CM; Cushen SJ; Orsso CE; Ryan AM
Proc Nutr Soc; 2016 May; 75(2):188-98. PubMed ID: 26743210
[TBL] [Abstract][Full Text] [Related]
11. Assessment of sarcopenia and changes in body composition after neoadjuvant chemotherapy and associations with clinical outcomes in oesophageal cancer.
Yip C; Goh V; Davies A; Gossage J; Mitchell-Hay R; Hynes O; Maisey N; Ross P; Gaya A; Landau DB; Cook GJ; Griffin N; Mason R
Eur Radiol; 2014 May; 24(5):998-1005. PubMed ID: 24535076
[TBL] [Abstract][Full Text] [Related]
12. Muscle contractile and metabolic dysfunction is a common feature of sarcopenia of aging and chronic diseases: from sarcopenic obesity to cachexia.
Biolo G; Cederholm T; Muscaritoli M
Clin Nutr; 2014 Oct; 33(5):737-48. PubMed ID: 24785098
[TBL] [Abstract][Full Text] [Related]
13. Impact of sarcopenia status of muscle-invasive bladder cancer patients on kidney function after neoadjuvant chemotherapy.
Regnier P; DE Luca V; Brunelle S; Sfumato P; Walz J; Rybikowski S; Maubon T; Branger N; Fakhfakh S; Durand M; Gravis G; Pignot G
Minerva Urol Nephrol; 2021 Apr; 73(2):215-224. PubMed ID: 32083413
[TBL] [Abstract][Full Text] [Related]
14. Low body mass index and sarcopenia associated with dose-limiting toxicity of sorafenib in patients with renal cell carcinoma.
Antoun S; Baracos VE; Birdsell L; Escudier B; Sawyer MB
Ann Oncol; 2010 Aug; 21(8):1594-1598. PubMed ID: 20089558
[TBL] [Abstract][Full Text] [Related]
15. Are sarcopenia, obesity and sarcopenic obesity predictive of outcome in patients with colorectal liver metastases?
Lodewick TM; van Nijnatten TJ; van Dam RM; van Mierlo K; Dello SA; Neumann UP; Olde Damink SW; Dejong CH
HPB (Oxford); 2015 May; 17(5):438-46. PubMed ID: 25512239
[TBL] [Abstract][Full Text] [Related]
16. Sarcopenic obesity: hidden muscle wasting and its impact for survival and complications of cancer therapy.
Baracos VE; Arribas L
Ann Oncol; 2018 Feb; 29(suppl_2):ii1-ii9. PubMed ID: 29506228
[TBL] [Abstract][Full Text] [Related]
17. Associations of Sarcopenia and Sarcopenic Obesity With Metabolic Syndrome Considering Both Muscle Mass and Muscle Strength.
Lee J; Hong YP; Shin HJ; Lee W
J Prev Med Public Health; 2016 Jan; 49(1):35-44. PubMed ID: 26841883
[TBL] [Abstract][Full Text] [Related]
18. Skeletal muscle mass loss and dose-limiting toxicities in metastatic colorectal cancer patients.
Kurk S; Peeters P; Stellato R; Dorresteijn B; de Jong P; Jourdan M; Creemers GJ; Erdkamp F; de Jongh F; Kint P; Simkens L; Tanis B; Tjin-A-Ton M; Van Der Velden A; Punt C; Koopman M; May A
J Cachexia Sarcopenia Muscle; 2019 Aug; 10(4):803-813. PubMed ID: 31094083
[TBL] [Abstract][Full Text] [Related]
19. Skeletal Muscle Loss during Neoadjuvant Chemotherapy Is an Independent Risk Factor for Postoperative Infectious Complications in Patients with Advanced Esophageal Cancer.
Motoori M; Fujitani K; Sugimura K; Miyata H; Nakatsuka R; Nishizawa Y; Komatsu H; Miyazaki S; Komori T; Kashiwazaki M; Iwase K; Yano M
Oncology; 2018; 95(5):281-287. PubMed ID: 30149394
[TBL] [Abstract][Full Text] [Related]
20. Is cachexia associated with chemotherapy toxicities in gastrointestinal cancer patients? A prospective study.
da Rocha IMG; Marcadenti A; de Medeiros GOC; Bezerra RA; Rego JFM; Gonzalez MC; Fayh APT
J Cachexia Sarcopenia Muscle; 2019 Apr; 10(2):445-454. PubMed ID: 30924270
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
